Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, February 4 , 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the second fiscal quarter ended December 31, 2004.  The Company also reported several

Warren Chaunce Bogard, Jr., Ph.D. Appointed to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 4, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that Warren Chaunce Bogard, Jr., Ph.D. has been appointed to the Company's Board of Directors.

Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, February 3, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call tomorrow, Friday, February 4, 2005 at 11:00 a.m. (EST).

-- Safety Endpoint for TRC Product Reached; Trial Expanded --

Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 31, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Friday, February 4, 2005 at 11:00 a.m. (EST). Aastrom's call will begin with brief presentations

-- Aastrom Stem Cell Product's Progress on Clinical Pathway Not Impacted --

-- Patent Extends Coverage from Stem Cell Population to Dendritic Cells --

-- Final $12 Million Tranche Completed at Premium to Market --

-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs --

Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary Ann Arbor, Michigan, and Berlin, Germany, December 9, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Zellera AG (Zellera), its wholly-owned subsidiary, today announced that Gunter